The experience of interleukin-1 inhibition in patients with familial Mediterranean fever

Abstract

This study aimed to present our single-center experience of anakinra and canakinumab treatment in patients with Familial Mediterranean fever (FMF). This study included 48 patients who were treated with anti-interleukin-1 (antiIL-1) treatment for at least six months. Initially, all patients with colchicineresistant or intolerant FMF were received anakinra treatment. Then those resistant to anakinra were given canakinumab treatment. Of the 48 (female/male:29/19) patients using anti-IL-1, their age was 31.2 ± 10.7 years, the duration of drug use was 15±8 months. 30 patients were already using anakinra and 18 patients were using canakinumab. Treatment was found to be switched to canakinumab in 9 patients due to non-adherence to daily injection, and inadequate response to anakinra in 9 patients. After the anti-IL-1 treatment the number of attacks, erythrocyte sedimentation rate, C-reactive protein, fibrinogen levels, colchicine dose and proteinuria (for all p<0.001) were decreased. Anti-IL-1 treatment is effective for controlling attacks and reducing proteinuria in patients with colchicine-resistant or intolerant FMF. In addition, canakinumab appears to be an alternative treatment option when there is a inconvenience to daily injection or resistance to anakinra treatment.

Keywords

• familial Mediterranean fever
• interleukin-1 inhibition
• anakinra
• canakinumab

References

1. Reference1 Abderrazak, A., Syrovets, T., Couchie, D., El Hadri, K., Friguet, B., Simmet, T., Rouis, M., 2015. NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol. 4, 296–307.
2. Reference2 Akar, S., Cetin, P., Kalyoncu, U., Karadag, O., Sari, I., Cınar, M., Yilmaz, S., Onat A.M., Kisacik, B., Erden, A., Balkarli, A., Kucuksahin, O., Oner, S.Y., Senel, S., Tufan, A., Direskeneli, H., Oksuz, F., Pehlivan, Y., Bayindir, O., Keser, G., Aksu, K., Omma, A., Kasifoglu, T., Unal, A.U., Yildiz, F., Balci, M.A., Yavuz, S., Erten, S., Ozgen, M., Sayarlıoglu, M., Dogru, A., Yildirim, G., Oner, F.A., Tezcan, M.E., Pamuk, O.N., Onen, F., 2018. Nationwide Experience with Off-Label Use of Interleukin-1 Targeting Treatment in familial Mediterranean fever Patients. Arthritis Care Res. 70, 1090-4.
3. Reference3 Bozkurt, Y., Demir, A., Erman, B., Gul, A., 2015. Unified modeling of familial Mediterranean fever and cryopyrin associated periodic syndromes. Comput Math Methods Med. 2015, 893507.
4. Reference4 Cazeneuve, C., Ajrapetyan, H., Papin, S., Roudot-Thoraval, F., Genevieve, D., Mndjoyan, E., Papazian, M., Sarkisian, A., Babloyan, A., Boissier, B., Duquesnoy, P., Kouyoumdjian, J.C., Girodon-Boulandet, E., Grateau, G., Sarkisian, T., Amselem, S., 2000. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am j Hum Genet. 67, 1136-43.
5. Reference5 Cerquaglia, C., Diaco, M., Nucera, G., La Regina, M., Montalto, M., Manna, R., 2005. Pharmacological and clinical basis of treatment of familial Mediterranean fever (FMF) with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy. 4, 117-24.
6. Reference6 Chae, J.J., Aksentijevich, I., Kastner, D.L., 2009. Advances in the understanding of familial Mediterranean fever and possibilities for targeted treatment. Br J Haematol. 146, 467-78.
7. Reference 7 Cronstein, B.N., Terkeltaub, R., 2006. The inflammatory process of gout and its treatment. Arthritis Res Ther. 8(Suppl 1), S3.
8. Reference8 Franchi, L., Eigenbröd, T., Munoz-Planillo, R., Nurez, G., 2009. The inflammasome; a caspase-1-activation platform that regulates immune response and disease pathogenesis. Nat Immunol. 10, 241-7.

9. Reference9 Kucuksahin, O., Yildizgoren, M.T., Ilgen, U., Ates, A., Kinikli, G., Turgay, M., Erten, S., 2017. Anti-interleukin-1 treatment in 26 patients with refractory familial Mediterranean fever. Mod Rheumatol. 27, 350-5.
10. Reference10 Nuki, G., 2008. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep. 10, 218-27.
11. Reference11 Ozdogan, H., Ugurlu, S., 2017. Canakinumab for the treatment of familial Mediterranean fever. Expert Rev Clin Immunol. 13, 393-404.
12. Reference12 Ozen, S., Bilginer, Y., Aktay Ayaz, N., Calguneri, M., 2011. Anti-interleukin treatment for patients with familial Mediterranean fever resistant to colchicine. J.Rheumatol. 38, 516-8.
13. Reference13 Ozen, S., Demirkaya, E., Erer, B., Livneh, A., Ben-Chetrit, E., Giancane, G., Ozdogan, H., Abu, I., Gattorno, M., Hawkins, P.N., Yuce, S., Kallinich, T., Bilginer, Y., Kastner, D., Carmona, L., 2016. EULAR recommendation for the management of familial Mediterranean fever. Ann Rheum Dis. 75, 644-51.
14. Reference14 Papin, S., Cuenin, S., Agostini, L., Martinon, F., Werner, S., Beer, H.D., Grütter C., Grütter, M., Tschopp, J., 2007. The SPRY domain of pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1 beta processing. Cell Death Differ. 14, 1457-66.
15. Reference15 Petrushkin, H., Stanford, M., Fortune, F., Jawad, A.S., 2016. Clinical Review: Familial Mediterranean Fever-An Overview of Pathogenesis, Symptoms, Ocular Manifestations, and Treatment. Ocul Immunol Inflamm. 24, 422-30.
16. Reference16 Sari, I., Birlik, M., Kasifoğlu, T., 2014. Familial Mediterranean fever: an updated review. Eur J Rheumatol. 1, 21-33.
17. Reference17 Seyahi, E., Ozdogan, H., Celik, S., Ugurlu, S., Yazici, H., 2006. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol 24(Suppl 42), 99-103.
18. Reference18 Sohar, E., Gafni, J., Pras, M., Heller, H., 1967. Familial Mediterranean fever a survey of 470 cases and review of the literatüre. Am J Med. 43, 227-53.
19. Reference19 Soylemezoglu, O., Arga, M., Fidan, K., Gonen, S., Emeksiz, H.C., Hasanoglu, E., Buyan, E., 2010. Unresponsiveness to colchicine treatment in patients with familial Mediterranean fever homozygous for the M694V mutation. J Rheumatol. 37, 182-9.
20. Reference20 Stankovic, S.K., Delmas, Y., Torres, P.U., Peltier, J., Pelle, G., Jéru, I., Colombat, M., Grateau, G., 2012. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant. 27, 1898-901.
21. Reference21 TerHaar, N., Lachmann, H., Özen, S., Woo, P., Uziel, Y., Modesto, C., Kone-Paut, I., Cantarini, L., Insalaco, A., Neven, B., Hofer, M., Rigante, D., Al-Mayouf, S., Touitou, I., Gallizzi, R., Papadopoulou-Alataki, E., Martino, S., Kuemmerle-Deschner, J., Obici, L., Iagaru, N., Simon, A., Nielsen, S., Martini, A., Ruperto, N., Gattorno, M., Frenkel, J., 2013. Treatment of autoinflammatory disease: result from the Eurofever Registry and a literatüre review. Ann Rheum Dis. 72, 678-85.
22. Reference22 The French FMF Consortium, 1997. A candidate gene for familial Mediterranean fever. Nat Genet. 17, 25-31.
23. Reference 23 The International FMF Consortium., 1997. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 90, 797-807.
24. Reference24 Urieli-Shoval, S., Linke, R.P., Matzner, Y., 2000. Expression and function of serum amyloid A, a major acute phase protein, in normal and disease states. Curr Opin Hematol. 7, 64-9.
25. Reference25 Van der Hilst, J.C., Simon, A., Drenth, J.P., 2005. Herediaty periodic fever and reactive amyloidosis. Clin Exp Med. 5, 87-98.
26. Reference26 Zemer, D., Pras, M., Sohar, E., Modan, M., Cabili, S., Gafni, J., 1986. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N. Engl. J Med. 314, 1001-5.